July 24 2013 | By Márcio Barra
Roche has announced that its experimental leukemia drug GA101, or obinutuzumab, used in combination with chemotherapy, was better than Rituxan at helping people with chronic lymphocytic leukemia live longer without their disease worsening, according to the results from the second phase of the clinical trial. Both drugs were tested and compared in combination with chlorambucil.
The trial, named CLL11, is a phase III, multicenter, open-label, randomized three-arm study investigated in 781 previously untreated people with chronic lymphocytic leukemia and co-existing medical conditions who are in need of therapy. The study included two stages of analysis, with the first stage results being reported at the start of this month. Data from the first stage showed that patients taking Obinutuzumab had a 86%reduction in the risk of disease worsening or death when combined with chlorambucil chemotherapy compared to chlorambucil alone in previously untreated people with chronic…
View original post 240 more words
Reblogged this on MedCheminSingapore by Sushma Wang.
LikeLike
By sushmawang on July 27, 2013 at 3:52 am
Reblogged this on MED.CHEM in BURMA.
LikeLike
By sonsondaimari on July 27, 2013 at 3:54 am
Reblogged this on MedCheminAustralia.
LikeLike
By medchemnintabelle on July 27, 2013 at 3:57 am
Reblogged this on Med.Chem in Nepal.
LikeLike
By sitanepali on July 27, 2013 at 3:59 am
Reblogged this on Srilanka-Chem.
LikeLike
By srilankachem on July 27, 2013 at 4:02 am
Reblogged this on Srilanka-Chem.
LikeLike
By srilankachem on July 27, 2013 at 4:04 am
[…] Roche’s new leukaemia drug, Obinutuzumab, superior to Rituxan in clinical trial […]
LikeLike
By FDA approves Gazyva for chronic lymphocytic leukemia « New Drug Approvals on November 2, 2013 at 3:41 am